INTRODUCTION
============

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was originally identified as a member of the TNF family that can induce apoptosis in various cancer cells [@B001], [@B002]. TRAIL mediated apoptotic induction in most transformed tumor cells occurs by stimulation of its cognate receptors DR4 (or TRAILR1) and DR5 (or TRAILR2). However, TRAIL related induction of apoptosis in normal cells is known to be limited by a yet unknown mechanism. The active form of TRAIL is a homo-trimer that triggers trimerization of DR4 or DR5 and subsequent recruitment of FADD and caspase-8 to form the death-inducing signaling complex (DISC) [@B003]-[@B005], which ultimately results in apoptotic cell death.

TRAIL is a type II transmembrane protein, which can be produced in a soluble form by protease-mediated cleavage of its extracellular region or by bacterial expression of recombinant forms that encompass its extracellular region [@B001], [@B002]. Structural studies of TRAIL have revealed that it forms a trimer, which further bind to the trimeric DR5 protein [@B006]-[@B008]. TRAIL can form an apoptosis-inducing trimer in its native soluble form. Researchers have tried to stabilize this trimeric state of the soluble TRAIL by fusing trimerization motifs such as the isoleucine zipper (ILz) trimerization motif [@B009], [@B010] or the tenascin-C-derived trimerization motif [@B011]. Furthermore, the apoptosis-inducing activity of soluble TRAIL has been shown to be greatly enhanced by oligomerization of soluble Flag-tagged TRAIL plus Flag-antibodies [@B011]. Thus, the trimerization of TRAIL as well as oligomerization of its trimeric form appears to be the key determinants of its apoptosis-inducing activity.

In this report, we developed a novel ILz(6):TRAIL protein containing the hexamer formation domain of the isoleucine zipper motif (which may exist in two trimeric forms) followed by an extracellular region of the native TRAIL protein (amino acids 114-281). Unexpectedly, we found that ILz(6):TRAIL can form trimers, hexamers, and various multimers. Further, we showed that the apoptosis-inducing activity of soluble TRAIL is potentiated by its multimerization.

RESULTS
=======

Generation of recombinant ILz(6):TRAIL
--------------------------------------

TRAIL is a homo-trimeric membrane protein that is known to induce apoptosis in various tumor cells by binding to its cognate trimeric DR5 receptor. Recombinant soluble TRAIL composed of the extracellular region of TRAIL (amino acids 114-281) killed tumor cells. Fusion of the trimerization motif of an isoleucine zipper motif at the N-terminal region of TRAIL led to enhanced trimer formation [@B009], [@B010]. Based on this we assume that owing to the presence of a pre-oligomerized state the hexameric TRAIL protein (composed of two TRAIL trimeric units, amino acids 114-281) possibly displays a strong cytotoxic activity. The addition of a cysteine residue to the trimerization motif of an isoleucine zipper has been shown to form a hexamer [@B012], [@B013]. In order to generate a recombinant hexameric TRAIL protein (amino acid 114-281), the hexamerization motif of the isoleucine zipper was fused to TRAIL (114-281) at its N-terminal region resulting in ILz(6):TRAIL ([Fig. 1](#F001){ref-type="fig"}A). The recombinant ILz(6):TRAIL protein was expressed in *E. coli* BL21(DE3) and purified using a Ni-NTA His affinity column ([Fig. 1](#F001){ref-type="fig"}B). Recombinant ILz(6):TRAIL efficiently induced cell death in HCT116 ([Fig. 1](#F001){ref-type="fig"}C) and BJAB cells ([Fig. 1](#F001){ref-type="fig"}D). Furthermore, ILz(6):TRAIL showed a more potent cytotoxic activity compared to the recombinant TRAIL protein (amino acids 114-281; hereafter referred as TRAIL) in BJAB cells ([Fig. 1](#F001){ref-type="fig"}D). Additionally, the recombinant ILz(6):TRAIL showed enhanced cytotoxic activity on BJAB cells compared to recombinant TRAIL, which does not possess an isoleucine zipper hexamerization motif ([Fig. 1](#F001){ref-type="fig"}E).

![Development of ILz(6):TRAIL. (A) Schematic representation of the ILz(6):TRAIL protein. The 6xHis-tag was essential for Ni-NTA affinity purification; ILz(6) represents the isoleucine zipper hexamerization motif and TRAIL (114-281) represents the extracellular region of human TRAIL amino acids 114-281; (B) Purification of the recombinant ILz(6):TRAIL protein. The bacterial expression vector pET23a(+):ILz(6): TRAIL was transformed into *E. coli* BL21 (DE3) cells and induced with IPTG. Recombinant ILz(6):TRAIL was purified using a Ni-NTA His-binding affinity column; (C) HCT116 cells were treated overnight with recombinant ILz(6):TRAIL following by recording light microscope images; (D) Activity analysis of recombinant ILz(6):TRAIL. BJAB cells were treated with the the indicated amounts of purified recombinant ILz(6):TRAIL for 2 hours and cell death was determined using the XTT assay; (E) Comparison of the apoptosis-inducing activities of TRAIL and ILz(6):TRAIL. BJAB cells were treated with recombinant TRAIL or ILz(6): TRAIL for 18 hours and cell death was measured using the XTT assay.](BMB-49-282-g001){#F001}

Multimerization of recombinant ILz(6):TRAIL
-------------------------------------------

In order to examine the multimerization status of the recombinant proteins, ILz(6):TRAIL or TRAIL were subjected to crosslinking with Bismaleimidohexane (BMH) followed by separation on SDS-PAGE. ILz(6):TRAIL was cross-linked more favorably compared to TRAIL ([Fig. 2](#F002){ref-type="fig"}A), indicating that in comparison to TRAIL, ILz(6):TRAIL was a well-formed multimer. These results, however, did not conclusively determine whether the ILz(6):TRAIL protein existed in a trimeric or a hexameric form.

![Multimerization of ILz(6):TRAIL. (A) Recombinant ILz(6):TRAIL and recombinant TRAIL proteins were crosslinked with BMH and subjected to SDS-PAGE followed by staining with Coomassie Brilliant Blue. Monomers, dimers, and trimers of TRAIL and ILz(6):TRAIL are indicated; (B) Size fractionation of ILz(6):TRAIL. Recombinant ILz(6): TRAIL was subjected to size exclusion chromatography and the indicated relative molecular weights are comparable to molecular weight standards of dextran. (C) Multimeric form of Lz(6):TRAIL was obtained by size exclusion chromatography as described above. Sedimentation velocity AUC was performed, and AUC data were analyzed by continuous size distribution analysis using SEDFIT software (available at <http://www.analyticalultracentrifugation.com>).](BMB-49-282-g002){#F002}

Because the N-terminus of the ILz(6) motif contains a cysteine residue, we expected that this cysteine residue may lead to the formation of disulfide bonds between the trimeric state of ILz(6):TRAIL and thereby result in single or multiple units (trimers, hexamers, nonamers, dodecamers, etc.) of the trimeric ILz(6):TRAIL. Size exclusion chromatography separated the various multimeric states of ILz(6):TRAIL, which was found to form not only trimers and hexamers, but also mega-multimers ([Fig. 2](#F002){ref-type="fig"}B). Since trimers, hexamers, and mega-multimers were found abundantly, we concluded that depending on the conditions of purification, the three multimeric forms of ILz(6): TRAIL were interchangeable. To determine the multimeric states of mega-multimer fraction of ILz(6):TRAIL, sedimentation velocity experiments were carried out using analytical ultracentrifugation (AUC). The AUC results indicated that the fraction of ILz(6):TRAIL mega-multimers contain various multimeric forms including not only trimer and hexamer, but also 12-mer, 18-mer, 24-mer, 33-mer, and 45-mer. It is likely that the presence of cysteine residue at N-terminus of isoleucine hexamerization motifs in ILz(6):TRAIL led to various multi-units of trimeric ILz(6):TRAIL being formed through disulfide bonds between trimeric forms of ILz(6):TRAIL as we expected ([Fig. 2](#F002){ref-type="fig"}C). Distribution of these multimeric forms of ILz(6): TRAIL appear to be dependent on *E. coli* culture conditions such as growth temperature and time, buffer composition, and purification temperature. However, the key factors that determine the varying multimeric states of ILz(6):TRAIL were not defined in detail.

Potentiation of ILz(6):TRAIL by multimerization
-----------------------------------------------

Several reports have shown that the cytotoxic activity of death ligands, including TRAIL, in various tumor cells is enhanced upon their multimerization. Thus, we expected the ILz(6):TRAIL multimer and trimer to possess the highest and lowest cytotoxic activity, respectively. Indeed, the multimer of ILz(6):TRAIL showed the highest cytotoxic activity in Jurkat, BJAB, and HeLa cells and the trimer showed the least activity in these tumor cells ([Fig. 3](#F003){ref-type="fig"}A-C). These results confirmed that multimerization of ILz(6):TRAIL potentiates its killing activity in tumor cells.

![ILz(6):TRAIL is a potent killer. Jurkat (A); BJAB (B); and HeLa (C) cells were treated with trimers, hexamers, or multimers of recombinant ILz(6):TRAIL and cell viability was measured by XTT assay.](BMB-49-282-g003){#F003}

Cell death-signaling pathways were monitored at different points in order to characterize the responsiveness of multimeric forms of ILz(6):TRAIL. Multimeric ILz(6):TRAIL resulted in an obvious chromatin condensation and morphological changes in Jurkat cells within 1 hour, whereas a higher response time of either 2 or 4 hours was needed for chromatin condensation in the presence of hexameric or trimeric ILz(6): TRAIL, respectively ([Fig. 4](#F004){ref-type="fig"}A). Furthermore, the cleaved forms of caspase-3 and caspase-8 appeared within 30 minutes in response to multimeric ILz(6):TRAIL, but not until 60 minutes or 2 hours in response to hexameric or trimeric ILz(6):TRAIL, respectively. Multimeric ILz(6):TRAIL alone was able to generate tBid within 60 minutes after treatment. These results clearly show that multimerization of ILz(6):TRAIL enhances its cytotoxic activity.

![ILz(6):TRAIL is a potent killer. (A) Jurkat cells were treated with trimers, hexamers, or multimers of recombinant ILz(6):TRAIL protein for indicated times and subjected to Hoechst staining. Cells were then imaged with a fluorescent or a DIC microscope. (B) Jurkat cells were treated with trimers, hexamers, or multimers (MT) of recombinant ILz(6):TRAIL protein for 30, 60, and 120 minutes. Cell lysates were then subjected to immunoblotting against caspase-8, caspase-3, Bid, and GAPDH.](BMB-49-282-g004){#F004}

DISCUSSION
==========

In this study, we showed that the recombinant ILz(6):TRAIL protein possesses superior cytotoxic activity compared to recombinant TRAIL. The presence of a hexamerization motif from the isoleucine zipper at the N-terminus of TRAIL prompts not just hexamerization but also multimerization of ILz(6):TRAIL, resulting in remarkable enhancement of the cytotoxic activity in various cancer cells. Size exclusion chromatography and AUC of ILz(6):TRAIL demonstrated that it can form not only trimeric or hexameric but also various multimeric forms. We believe that the cysteine residue of the hexamerization motif in ILz(6):TRAIL leads to these various multimeric forms of ILz(6): TRAIL. We speculate that one-unit of trimeric ILz(6):TRAIL is likely to form two-units of trimeric ILz(6):TRAIL by disulfide bonding, which then accelerates the formation of various multi-units of trimeric ILz(6):TRAIL. This may be attributed to favorable disulfide bond cross-linking between one- and twounits of trimeric ILz(6):TRAIL.

Previous studies have shown that artificial trimerization of soluble trimeric ligands such as CD40L [@B014], GITR [@B015], FasL [@B016], and TRAIL [@B010] mediated by the isoleucine zipper trimerization motif can enhance their biological activity. Consistent with previous reports, the multimeric forms of ILz(6):TRAIL showed superior cytotoxic activities compared to their lower multimeric counterparts. The multimerization of ILz(6):TRAIL also resulted in rapid signaling events such as activation of caspases, tBid generation, and chromatin condensation. Although the exact reason and mechanism associated with high cytotoxicity of multimeric ILz(6):TRAIL forms is not clear, we speculate that a pre-multimerized ILz(6):TRAIL could facilitates the multimerization of DR5 on the cell surface. The facilitated multimerization of DR5 on the cell surface by multimeric ILz(6):TRAIL could, in turn, ease to form the death-inducing signaling complex (DISC) and/or to increase the stability of DISC complex in the cytoplasmic side of DR5, ultimately resulting in the early activation of caspase-8.

Taken together, our results indicate that the multimerization of ILz(6):TRAIL can potentiate the biological activity of TRAIL by accelerating the induction of cell death signaling pathways.

MATERIALS AND METHODS
=====================

Construction of ILz(6):TRAIL expression vectors
-----------------------------------------------

cDNA, encoding amino acids 114 -- 281 of human TRAIL, was amplified by reverse transcriptase -- polymerase chain reaction (RT-PCR) using total RNA isolated from HeLa cells. The following primers were used: hTRAIL(114):Sma1 (GGGCCCGGGGT GAGAGAAAGAGGTCCTCAG) and hTRAIL(281):EcoR1 (CCC GAATTCTTAGCCAACTAAAAAGGCCC). The amplified TRAIL cDNA was cloned into a modified version of pET23a(+) bearing a 6xHis tag at the 5'end of the multi cloning site. The synthetic oligonucleotide encoding the isoleucine hexamerization motif (ATGTGCGGAGGAAAGCAAATCGAAGACAAGATAGA AGAAATCCTATCAAAGATCTACCACATCGAAAACGAGATC GCACGAATCAAGAAGCTAATCGGAGAA) was cloned into the SmaI and EcoRV sites of the modified pET23a(+) vector, whereas the PCR-amplified DNA, encoding human TRAIL amino acids114 -- 281, was cloned into pET23a(+):ILz(6) at EcoRV and BamHI sites and has been referred to as pET23a(+): ILz(6):TRAIL.

Purification of recombinant TRAIL or ILz(6):TRAIL
-------------------------------------------------

*E. coli* BL21 (DE3) cells were transformed with pET23a(+): TRAIL or pET23a(+):ILz(6):TRAIL vectors and cultured in LB media at 28℃ for 2 days in the presence of IPTG. Cells were then harvested by centrifugation (5,000 × *g* for 5 min at 4℃) and protein purification was performed using Ni-NTA His binding resins (Novagen, Carlsbad, CA, USA), according to the manufacturer\'s instructions.

Size exclusion chromatography
-----------------------------

The purified recombinant ILz(6):TRAIL proteins were put through a Sephacryl-S200 size exclusion chromatography column (GE Healthcare Life Sciences, Cat. No. 17-0584-01). The column was operated with an AKTA-Prime Plus Liquid Chromatography System (GE Healthcare Life Sciences, Sweden). The total volume of the collected fractions was 109.9 ml and the void volume was 39.8 ml.

Analytical ultracentrifugation (AUC)
------------------------------------

A multimeric form of Lz(6):TRAIL was obtained by size exclusion chromatography as described above, and was dialysed in buffer containing 20 mM Tris-Cl pH 7.5 and 50 mM NaCl for analytical ultracentrifugation. Sedimentation velocity AUC experiments were performed at 20℃ using a Beckman XL-A ultracentrifuge (Palo Alto, CA, USA) using an AN-60 Ti fourhole rotor. Absorbance scans were taken at 30,000 rpm for 72 hrs. AUC data were analyzed by continuous size distribution analysis using SEDFIT software (available at [www.analyticalultracentrifugation.com](www.analyticalultracentrifugation.com)).

Cell culture and XTT assay
--------------------------

BJAB lymphoma cells (a generous gift from Genentech, San Francisco, CA, USA) were cultured in phenol red free RPMI medium (Welgene, Daegu, S. Korea) containing 10% fetal bovine serum, 10 units/ml penicillin, and 1 mg/ml streptomycin (all purchased from Gendepot, Barker, TX, USA). For the cell killing activity assay, BJAB cells (1.5 × 10^4^ cells/ml) were plated and treated with recombinant TRAIL or ILz(6):TRAIL. XTT solution (Promega, Madison, WI, USA) was then added and absorbances were monitored at 493 nm using a TECAN Infinite M200 monochromator (Tecan, Mannedorf, Switzerland).

Statistical analysis
--------------------

Results are reported as means ± SD. The Student's t test was used to evaluate differences between more than two groups. Statistical significance was accepted for P values ＜ 0.05.
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